(PPI) Use: A Call for Root-Cause Solutions

Introduction

Proton pump inhibitors, including omeprazole, esomeprazole and pantoprazole, are among the most commonly prescribed medications worldwide. Their mechanism of action involves irreversible inhibition of the gastric H+/K+ ATPase, leading to profound and long-lasting reduction in gastric acid secretion.

Although PPIs remain first-line therapy for peptic ulcer disease, H. pylori–associated ulcers, Zollinger–Ellison syndrome, Barrett’s esophagus and erosive esophagitis, concern arises with chronic use beyond established medical necessity. Stomach acid is essential for nutrient absorption, protein digestion and immune defense, and its suppression has systemic consequences.

Rebound Hyperacidity

Reimer et al. (2009) demonstrated that healthy volunteers given PPIs for several weeks developed acid-related symptoms upon withdrawal, despite having no prior reflux disease. The authors attributed this to rebound acid hypersecretion, caused by compensatory hypergastrinemia (1).

This phenomenon can lead patients to believe their underlying condition has worsened, perpetuating long-term dependence.

Nutrient Deficiencies

Several clinical studies have identified impaired absorption of vitamin B12 in long-term PPI users due to reduced gastric acidity, which is required to liberate B12 from dietary proteins.

• Hirschowitz et al. (2008) demonstrated significant B12 deficiency in chronic omeprazole users (2).
• den Elzen et al. (2008) reported that older adults on long-term PPIs had significantly lower serum B12 levels than non-users (3).

Hypochlorhydria has also been linked to impaired absorption of calcium, magnesium and iron, increasing the risk of anemia, osteoporosis and neuromuscular symptoms.

Cognitive Decline

Two large population-based studies have reported a statistical association between long-term PPI use and increased risk of dementia:

• Gomm et al. (2016), analyzing German health claims data, reported higher dementia incidence among long-term PPI users (4).
• Tai et al. (2017) found a similar association in a Taiwanese cohort (5).

These studies do not prove causation, but proposed mechanisms include B12 deficiency, altered amyloid metabolism and changes in cerebrospinal fluid pH.

Kidney and Cardiovascular Risk

Observational studies have identified significant correlations between chronic PPI use and kidney disease:

• Lazarus et al. (2016) reported increased risk of chronic kidney disease among PPI users in a large US cohort (6).
• Other studies have documented acute interstitial nephritis linked to PPIs.

In cardiovascular research:

• Charlot et al. (2010) found higher cardiovascular events among PPI users independent of clopidogrel use (7).

The mechanistic basis may involve endothelial dysfunction and inhibition of nitric oxide pathways.

Microbiome Disruption

Gastric acid acts as a critical antimicrobial barrier. PPIs raise gastric pH, increasing bacterial survival and altering gut microbial composition.

• Lombardo et al. (2010) documented a significant increase in small intestinal bacterial overgrowth (SIBO) among PPI users (8).
• Other studies have shown higher rates of Clostridium difficile infection in PPI users.

This shift in microbial ecology can negatively impact digestion, immune function and metabolic health.

Gastric Atrophy and Hypergastrinemia

Waldum et al. (2015) reviewed evidence showing that long-term acid suppression leads to elevated gastrin levels, fundic gland polyps and, in some cases, atrophic gastritis (9). Gastrin-driven mucosal proliferation is the body’s compensatory response to sustained acid suppression.

Drug Interactions

PPIs interact with the cytochrome P450 enzyme system, primarily CYP2C19 and CYP3A4. These interactions can alter blood levels of commonly prescribed drugs.

• Zhou et al. (2007) outlined clinically significant PPI interactions with clopidogrel, warfarin, diazepam, antifungals and HIV medications (10).

These effects may reduce therapeutic efficacy or increase toxicity.

Discussion

Although PPIs remain essential in many clinical scenarios, their long-term use should be approached with caution. Many symptoms attributed to “too much acid” are increasingly understood as dysfunctions of motility, mucosal protection or lower esophageal sphincter tone rather than excess acid production.

This recognition underscores the need for therapies that support digestive physiology rather than suppress it.

Root-cause approaches include:

• improving gastric motility
• supporting sphincter function
• reducing pressure buildup
• strengthening mucosal integrity
• optimizing microbiome balance

These mechanisms represent a more holistic, sustainable path for symptom reduction.

Conclusion

Growing scientific evidence suggests that chronic PPI therapy carries risks that extend beyond the gastrointestinal tract. This highlights the need for complementary or alternative strategies that restore rather than suppress digestive function.

Emerging polyphenol-based combinations, such as Re:flux, are designed to support motility, sphincter tone and mucosal health. While more research is needed, these approaches offer a promising direction for patients seeking long-term stability without the drawbacks of acid suppression.

A shift toward mechanism-focused, root-cause solutions may improve outcomes for millions living with chronic reflux symptoms.